Percutaneous coronary intervention in patients with acute coronary syndrome: Focus on bivalirudin

Vascular Health and Risk Management

Volumn 4, Issue 3, 2008, Pages 493-505

  Ramana, Ravi K ^a   Lewis, Bruce E ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Bivalirudin; Coronary intervention; Direct thrombin inhibitor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; INTEGRILLIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NADROPARIN; PLACEBO; PROTAMINE; STREPTOKINASE; THROMBIN BINDING DNA APTAMER; THROMBIN INHIBITOR; XIMELAGATRAN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANXIETY; BACKACHE; BLEEDING; BLOOD TRANSFUSION; BOLUS INJECTION; BRADYCARDIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FEVER; HEART INFARCTION; HEART REINFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTENSION; HYPOTENSION; IN-STENT RESTENOSIS; INSOMNIA; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NERVOUSNESS; PATHOPHYSIOLOGY; PELVIS PAIN SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK REDUCTION; SIDE EFFECT; STEADY STATE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VOMITING;

ACUTE CORONARY SYNDROME; ANEMIA; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; COMORBIDITY; CORONARY THROMBOSIS; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 47849093479     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Anand SX, Kim MC, Kamran M, et al. 2007. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol, 100:417-24.
2. Anderson JL, Adams CD, Amman EM, et al. 2007. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol, 50:e1-e157.
3. APPROVE. 2004. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day results. J Invasive Cardiol, 16, 651-6.
4. Arora UK, Dhir M. 2005. Direct thrombin inhibitors part 1 of 2. J Invasive Cardiol, 17:34-8.
5. Bates ER. 2004. Bivalirudin: an anticoagulant option for percutancous coronary intervention. Expert Rev Cardiovasc Ther, 2:153-62.
6. Bates SM, Weitz JI. 1998. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol, 82:12P-18P.
7. Becker DL, Fredenburgh JC, Stafford AR. et al. 1999. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem, 274:6226-33.
8. Bittl JA. 1995. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am Heart J, 130:658-65.
9. Bittl JA, Chaitman BR, Feit F, et al. 2001. Bivaliradin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J, 142:952-9.
10. Bittl JA, Strony J, Brinker JA, et al. 1995. Treatment with bivalirudin Hirulog. as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med, 333:764-9.
11. Brener SJ, Moliterno DJ, Lincoff AM, et al. 2004. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation, 110:994-8.
12. Burke AP, Farb A, Malcom GT, et al. 1998. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation, 97:2110-6.
13. Burke AP, Farb A, Malcom GT, et al. 1997. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med, 336:1276-82.
14. Cairns JA, Gent M, Singer J, et al. 1985. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med, 313:1369-75.
15. Cannon CP, Maraganore JM, Loscalzo J, et al. 1993. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol, 71:778-82.
16. CAPRIE. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRIE. CAPRIE Steering Committee. Lancet, 348, 1329-39.
17. Chamberlin JR, Lewis B, Leya F, et al. 1995. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol, 11:511-4.
18. Chong BH. 2003. Heparin-induced thrombocytopenia. J Thromb Haemost, 1:1471-8.
19. Cohen M, Adams PC, Parry G, et al. 1994. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation, 89:81-8.
20. Da L. 1989. Heparin binding and neutralizing proteins. Boca Raton, CRC Press.
21. De Romeuf C, Mazurier C. 1993. Heparin binding assay of von Willebrand factor vWF. in plasma milieu - evidence of the importance of the multimerization degree of vWF. Thromb Haemost, 69:436-40.
22. Di Nisio M, Middeldorp S, Buller HR. 2005. Direct thrombin inhibitors. N Engl J Med, 353:1028-40.
23. Dyke CM, Smedira NG, Koster A, et al. 2006. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J thorac Cardiovasc Surg, 131:533-9.
24. Eikelboom JW, Mehta SR, Anand SS, et al. 2006. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation, 114:774-82.
25. Eitzman DT, Chi L, Saggin L, et al. 1994. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation, 89:1523-9.
26. Eres A. 2006. Use of bivalirudin as the foundation anticoagulant during percutaneous peripheral interventions. J Invasive Cardiol, 18:125-8.
27. Fenton JW 2nd, Ofosu FA, Brezniak DV, et al. 1998. Thrombin and antithrombotics. Semin Thromb Hemost, 2487-91.
28. Ferguson JJ, Califf RM, Antman EM, et al. 2004. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA, 292:45-54.
29. Fox I, Dawson A, Loynds P, et al. 1993. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost, 69:157-63.
30. FRISC. 1996. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease FRISC study group. Lancet, 347, 561-8.
31. Furie B, Furie BC. 1992. Molecular and cellular biology of blood coagulation. N Engl J Med, 326:800-6.
32. Gibson CM, Morrow DA, Murphy SA, et al. 2006. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol, 47:2364-73.
33. Gibson CM, Ten Y, Murphy SA, et al. 2007. Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention A REPLACE-2 analysis. Am J Cardiol, 99:1687-90.
34. Gurfinkel EP, Manos EJ, Mejail RI, et al. 1995. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol, 26:313-8.
35. Gurm HS, Rajagopal V, Bhatt DL, et al. 2007. The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy. J Invasive Cardiol, 19:225-8.
36. Hirsh J. 1991. Heparin. N Engl J Med, 324:1565-74.
37. Hogg PJ, Bock PE. 1997. Modulation of thrombin and heparin activities by fibrin. Thromb Haemost, 77:424-33.
38. ISIS-2. 1988. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet, 2:349-60.
39. Jabr K, Johnson J, McDonald MH, et al. 2004. Plasma-modified ACT can be used to monitor bivalirudin Angiomax. anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. Journal of Extra-Corporeal Technology, 36:174-7.
40. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation.
41. Kumar R, Beguin S, Hemker HC. 1994. The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost, 72:713-21.
42. Kumar R, Beguin S, Hernker HC. 1995. The effect of fibrin clots and clotbound thrombin on the development of platelet procoagulant activity. Thromb Haemost, 74:962-8.
43. Lee PC, Kini AS, Ahsan C, et al. 2004. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Coll Cardiol, 44:541-6.
44. Lehman SJ, Chew DP. 2006. Bivalirudin in percutaneous coronary intervention. Vasc Health Risk Manag, 2:357-63.
45. Lewis HD Jr, Davis JW, Archibald DG, et al. 1983. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med, 309:396-403.
46. Lidon RM, Theroux P, Juneau M, et al. 1993. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation, 88:1495-501.
47. Lincoff AM, Bittl JA, Harrington RA, et al. 2003. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA, 289853-63.
48. Lincoff AM, Bittl JA, Kleiman NS, et al. 2004. Comparison of bivalirudin versus heparin during percutaneous coronary intervention the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial. Am J Cardiol, 93:1092-6.
49. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. 2002. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial CACHET. Am Heart J, 143:847-53.
50. Mahaffey KW, Lewis BE, Wildermann NM, et al. 2003. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia ATBAT. study: main results. J Invasive Cardiol, 15:611-6.
51. Manoukian SV, Feit F, Mehran R, et al. 2007. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol, 49:1362-8.
52. Maraganore JM, Bourdon P, Jablonski J, et al. 1990. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry, 29:7095-101.
53. McKechnie RS, Smith D, Montoye C, et al. 2004. Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation, 110:271-7.
54. Mehta SR, Yusuf S, Peters RJ, et al. 2001. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 358:527-33.
55. Merry AF. 2004. Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery. Semin Thromb Hemost, 30:337-46.
56. Merry AF, Raudkivi PJ, Middleton NG, et al. 2004. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg, 77:925-31; discussion 931.
57. Mirshahi M, Soria J, Soria C, et al. 1989. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood, 74:1025-30.
58. Oler A, Whooley MA, Oler J, et al. 1996. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA, 276:811-5.
59. Parry MA, Maraganore JM, Stone SR. 1994. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry, 33:14807-14.
60. Rao SV, O'Grady K, Pieper KS, et al. 2005. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol, 96:1200-6.
61. Reed MD, Bell D. 2002. Clinical pharmacology of bivalirudin. Pharmacotherapy, 22:105S-111S.
62. RISC. 1990. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet, 336:827-30.
63. Robson R. 2000. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol, 12(Suppl F):33F-6.
64. Rosamond W, Flegal K, Friday G, et al. 2007. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 115:e69-171.
65. Sakharov DV, Plow EF, Rijken DC. 1997. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem, 272, 14477-82.
66. Schaar JA, Muller JE, Falk E, et al. 2004. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J, 25:1077-82.
67. Schror K. 1993. The basic pharmacology of ticlopidine and clopidogrel. Platelets, 4:252-61.
68. Sciulli TM, Mauro VF. 2002. Pharmacology and clinical use of bivalirudin. Ann Pharmacother, 36:1028-41.
69. Sharma GV, Lapsley D, Vita JA, et al. 1993. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol, 72:1357-60.
70. Shen GX, XM, Fenton JW, et al. 1997. Effect of hirulog-1 on fibrinolysis and platelet deposition abstract. Atherosclerosis, 134:195.
71. Smedira NG, Dyke CM, Koster A, et al. 2006. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg, 131, 686-92.
72. Stella J, Stella D, Iaffaldano R, et al. 2006. The bivalirudin in the management of patients with ST-segment elevation acute myocardial infarction undergoing primary PCI BIAMI. Trial. Society of Cardiovascular Angiography and Interventions.
73. Stella JF, Stella RE, Iaffaldano RA, et al. 2004. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Invasive Cardiol, 16:451-4.
74. Stone GW. 2007. HORIZONS AMI: Bivalirudin reduces bleeding, adverse clinical events in STEMI. TCT. Washington, D.C.
75. Stone GW, McLaurin BT, Cox DA, et al. 2006. Bivalirudin for patients with acute coronary syndromes. N Engl J Med, 355:2203-16.
76. Stone GW, Ware JH, Bertrand ME, et al. 2007a. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA, 298:2497-506.
77. Stone GW, White HD, Ohman EM, et al. 2007b. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy ACUITY. trial. Lancet, 369:907-19.
78. Telford AM, Wilson C. 1981. Trial of heparin versus atenolol in prevention of myocardial intarction in intermediate coronary syndrome. Lancet, 1:1225-8.
79. Theroux P, Ouimet H, McCans J, et al. 1988. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med, 319:1105-11.
80. Theroux P, Waters D, Qiu S, et al. 1993. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation, 88:2045-8.
81. TIMI-8. 2002. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J, 143:229-34.
82. Topol EJ, Bonan R, Jewitt D, et al. 1993. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation, 87:1622-9.
83. Virmani R, Burke AP, Farb A, et al. 2006. Pathology of the vulnerable plaque. J Am Coll Cardiol, 47:C13-8.
84. Virmani R, Kolodgie FD, Burke AP, et al. 2000. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 20:1262-75.
85. Voeltz MD, Patel AD, Feit F, et al. 2007. Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention. Am J Cardiol, 99:1513-7.
86. Waksman R, Wolfram RM, Torguson RL, et al. 2006. Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH - a multicenter clinical trial. J Invasive Cardiol, 18:370-5.
87. Weitz JI. 1997. Low-molecular-weight heparins. N Engl J Med, 337:688-98.
88. Weitz JI, Hudoba M, Massel D, et al. 1990. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest, 86:385-91.
89. Weitz JI, Leslie B, Hudoba, M. 1998. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation, 97:544-52.
90. White H. 2001. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet, 358:1855-63.
91. Williams DO, Kirby MG, McPherson K. et al. 1986. Anticoagulant treatment of unstable angina. Br J Clin Pract, 40:114-6.
92. Yusuf S, Mehta SR, Chrolavicius S, et al. 2006a. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med, 354:1464-76.
93. Yusuf S, Mehta SR, Chrolavicius S, et al. 2006b. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA, 295:1519-30.
94. Yusuf S, Zhao F, Mehta SR, et al. 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 345:494-502.